Trump makes announcement on weight loss drug prices
Digest more
Some experts have blamed the issues on drastic staffing and budget cuts instituted by the Trump administration.
Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have access to them under two deals announced Thursday by the Trump administration.
The U.S. Food and Drug Administration said on Thursday it has awarded six more companies, including Eli Lilly and Novo Nordisk, special vouchers that will speed up the review of their medicines, bringing the total number of recipients to 15.
George Tidmarsh left the agency amid accusations of misusing his authority and after clashing with another top official.
ByHeart Inc. agreed to begin recalling two lots of the company’s Whole Nutrition Infant Formula, the Food and Drug Administration said in a statement.
(Reuters) -The director of the U.S. Food and Drug Administration's Center for Drug Evaluation and Research, George Tidmarsh, resigned on Sunday amid serious concerns about his personal conduct, a Department of Health and Human Services spokesperson told Reuters on Monday.
New professional guidance to the nation's pediatricians advises against using a drug in children with autism that many families are clamoring for after it was hyped by federal officials.
() -Rhythm Pharmaceuticals said on Friday the U. Food and Drug Administration has extended the review period for expanded approval of its drug, Imcivree, as a treatment for a rare form of obesity.